Trial Profile

A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary)
Indications Meniere's disease
Focus Adverse reactions
Sponsors Otonomy [CEASED]

Most Recent Events

13 Sep 2017 According to an Otonomy media release, all development activities for OTIVIDEX have been suspended including termination of ongoing clinical trials and pre-registration support efforts.
13 Sep 2017 Status changed from active, no longer recruiting to discontinued according to an Otonomy media release,
16 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com